[SCHEDULE 13G/A] Solid Biosciences Inc. SEC Filing
Solid Biosciences Inc. Schedule 13G/A filing by Commodore Capital entities
Commodore Capital LP and Commodore Capital Master LP filed an amendment to Schedule 13G reporting zero shares beneficially owned of Solid Biosciences Inc. (CUSIP 83422E204), representing 0.0% of the class. The filing lists the issuers' principal office at 500 Rutherford Avenue, Charlestown, Massachusetts, and gives filing addresses for the two filers in New York and the Cayman Islands. Both filers state no sole or shared voting or dispositive power over any shares and certify the securities were not acquired to influence control of the issuer. The filing is signed by Michael Kramarz for both entities and references a Joint Filing Agreement as an exhibit.
Solid Biosciences Inc. deposito Schedule 13G/A da parte di entit脿 Commodore Capital
Commodore Capital LP e Commodore Capital Master LP hanno presentato un emendamento al Schedule 13G dichiarando di possedere zero azioni di Solid Biosciences Inc. (CUSIP 83422E204), pari a 0,0% della classe. Il documento indica l'ufficio principale dell'emittente in 500 Rutherford Avenue, Charlestown, Massachusetts, e riporta gli indirizzi di notifica dei due soggetti a New York e nelle Isole Cayman. Entrambi affermano di non avere poteri di voto n茅 dispositivi, n茅 in modo esclusivo n茅 congiunto, sulle azioni e certificano che i titoli non sono stati acquisiti per influenzare il controllo dell'emittente. Il filing 猫 firmato da Michael Kramarz per entrambe le entit脿 e cita un Agreement di deposito congiunto come allegato.
Presentaci贸n Schedule 13G/A de Solid Biosciences Inc. por entidades de Commodore Capital
Commodore Capital LP y Commodore Capital Master LP presentaron una enmienda al Schedule 13G declarando la tenencia de cero acciones de Solid Biosciences Inc. (CUSIP 83422E204), equivalentes a 0,0% de la clase. La presentaci贸n indica la oficina principal del emisor en 500 Rutherford Avenue, Charlestown, Massachusetts, y proporciona las direcciones de tr谩mite de los dos presentantes en Nueva York y en las Islas Caim谩n. Ambos afirman no tener poder de voto ni dispositvo, ni exclusivo ni compartido, sobre ninguna acci贸n y certifican que los valores no fueron adquiridos para influir en el control del emisor. El documento est谩 firmado por Michael Kramarz por ambas entidades y menciona un Acuerdo de Presentaci贸n Conjunta como anexo.
Commodore Capital 瓿勳棿靷摛鞚� Solid Biosciences Inc. Schedule 13G/A 鞝滌稖
Commodore Capital LP鞕� Commodore Capital Master LP電� Schedule 13G 靾橃爼靹滊ゼ 鞝滌稖頃橃棳 Solid Biosciences Inc.(CUSIP 83422E204)鞐� 雽�頃� 氤挫湢 欤检嫕 靾� 0欤�, 歃� 齑濍 欷� 0.0%鞛勳潉 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 氚滍枆須岇偓鞚� 氤胳偓臧� 毵れ偓於旍劯旄犾＜ 彀办姢韮�鞖� 500 Rutherford Avenue鞐� 鞛堨潓鞚� 旮办灛頃橁碃, 霊� 鞝滌稖鞛愳潣 鞝滌稖 欤检唽電� 雺挫殨瓿� 旒�鞚措Ж 鞝滊弰搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞏戩浮 氇憪 雼弲 霕愲姅 瓿惦彊鞚� 鞚橁舶甓屄缝矘攵勱秾鞚� 鞐嗠嫟瓿� 氚濏瀳瓿� 鞛堨溂氅�, 頃措嫻 歃濌秾鞚� 氚滍枆須岇偓 歆�氚办棎 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑頃橃 鞎婌晿鞚岇潉 歃濍獏頃╇媹雼�. 鞝滌稖靹滊姅 霊� 氩曥澑鞚� 鞙勴暣 Michael Kramarz臧� 靹滊獏頄堨溂氅� 瓿惦彊 鞝滌稖 瓿勳暯靹滊ゼ 觳秬鞛愲搿� 鞏戈笁頃╇媹雼�.
D茅p么t Schedule 13G/A de Solid Biosciences Inc. par des entit茅s Commodore Capital
Commodore Capital LP et Commodore Capital Master LP ont d茅pos茅 un amendement au Schedule 13G d茅clarant d茅tenir z茅ro action de Solid Biosciences Inc. (CUSIP 83422E204), soit 0,0 % de la cat茅gorie. Le dossier indique le si猫ge principal de l'茅metteur au 500 Rutherford Avenue, Charlestown, Massachusetts, et fournit les adresses de d茅p么t des deux d茅clarants 脿 New York et aux 卯les Ca茂mans. Les deux d茅clarants pr茅cisent ne d茅tenir ni pouvoir de vote ni pouvoir de disposition, ni exclusif ni partag茅, sur aucune action et certifient que ces titres n'ont pas 茅t茅 acquis dans le but d'influencer le contr么le de l'茅metteur. Le d茅p么t est sign茅 par Michael Kramarz pour les deux entit茅s et renvoie 脿 un accord de d茅p么t conjoint en annexe.
Schedule 13G/A von Solid Biosciences Inc. eingereicht durch Commodore Capital-Einheiten
Commodore Capital LP und Commodore Capital Master LP haben eine 脛nderung zum Schedule 13G eingereicht und melden dabei null Aktien von Solid Biosciences Inc. (CUSIP 83422E204) 鈥� entsprechend 0,0% der Klasse. Die Einreichung nennt den Hauptsitz des Emittenten in 500 Rutherford Avenue, Charlestown, Massachusetts, und gibt die Einreichungsadressen der beiden Melder in New York und auf den Cayman Islands an. Beide geben an, weder alleinige noch gemeinsame Stimmberechtigung oder Verf眉gungsgewalt 眉ber irgendwelche Aktien zu besitzen, und best盲tigen, dass die Wertpapiere nicht zum Zwecke der Einflussnahme auf die Kontrolle des Emittenten erworben wurden. Das Dokument ist f眉r beide Einheiten von Michael Kramarz unterzeichnet und verweist auf eine gemeinsame Einreichungsvereinbarung als Anhang.
- Full disclosure compliance: The amendment is signed and includes a Joint Filing Agreement exhibit.
- Clear statement of non-ownership: Both filers report 0.00 shares and 0.0% of the class, removing ambiguity about current holdings.
- None.
Insights
TL;DR: The amendment reports no beneficial ownership, indicating the filers hold 0.0% of SLDB and assert no control intent.
The Schedule 13G/A discloses that Commodore Capital LP and Commodore Capital Master LP each report zero shares beneficially owned and 0.0% of the class. All columns for sole and shared voting and dispositive power are reported as 0.00. The filing includes requisite issuer and filer addresses and a certification that the securities were not acquired to influence control. For investors, this filing is a routine ownership disclosure with no direct impact on capitalization or control dynamics because no holdings are reported.
TL;DR: Formal compliance filing filed and signed; no reported ownership or group activity.
The document contains a signed certification and an exhibit reference to a Joint Filing Agreement, meeting formal disclosure requirements for Schedule 13G/A amendments. The filers classify themselves as applicable types (IA, PN and PN) on the cover pages and explicitly state not applicable for group identification, ownership over 5%, and related items. The submission documents that neither filer holds voting or dispositive power over Solid Biosciences common stock as of the reported event date.
Solid Biosciences Inc. deposito Schedule 13G/A da parte di entit脿 Commodore Capital
Commodore Capital LP e Commodore Capital Master LP hanno presentato un emendamento al Schedule 13G dichiarando di possedere zero azioni di Solid Biosciences Inc. (CUSIP 83422E204), pari a 0,0% della classe. Il documento indica l'ufficio principale dell'emittente in 500 Rutherford Avenue, Charlestown, Massachusetts, e riporta gli indirizzi di notifica dei due soggetti a New York e nelle Isole Cayman. Entrambi affermano di non avere poteri di voto n茅 dispositivi, n茅 in modo esclusivo n茅 congiunto, sulle azioni e certificano che i titoli non sono stati acquisiti per influenzare il controllo dell'emittente. Il filing 猫 firmato da Michael Kramarz per entrambe le entit脿 e cita un Agreement di deposito congiunto come allegato.
Presentaci贸n Schedule 13G/A de Solid Biosciences Inc. por entidades de Commodore Capital
Commodore Capital LP y Commodore Capital Master LP presentaron una enmienda al Schedule 13G declarando la tenencia de cero acciones de Solid Biosciences Inc. (CUSIP 83422E204), equivalentes a 0,0% de la clase. La presentaci贸n indica la oficina principal del emisor en 500 Rutherford Avenue, Charlestown, Massachusetts, y proporciona las direcciones de tr谩mite de los dos presentantes en Nueva York y en las Islas Caim谩n. Ambos afirman no tener poder de voto ni dispositvo, ni exclusivo ni compartido, sobre ninguna acci贸n y certifican que los valores no fueron adquiridos para influir en el control del emisor. El documento est谩 firmado por Michael Kramarz por ambas entidades y menciona un Acuerdo de Presentaci贸n Conjunta como anexo.
Commodore Capital 瓿勳棿靷摛鞚� Solid Biosciences Inc. Schedule 13G/A 鞝滌稖
Commodore Capital LP鞕� Commodore Capital Master LP電� Schedule 13G 靾橃爼靹滊ゼ 鞝滌稖頃橃棳 Solid Biosciences Inc.(CUSIP 83422E204)鞐� 雽�頃� 氤挫湢 欤检嫕 靾� 0欤�, 歃� 齑濍 欷� 0.0%鞛勳潉 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 氚滍枆須岇偓鞚� 氤胳偓臧� 毵れ偓於旍劯旄犾＜ 彀办姢韮�鞖� 500 Rutherford Avenue鞐� 鞛堨潓鞚� 旮办灛頃橁碃, 霊� 鞝滌稖鞛愳潣 鞝滌稖 欤检唽電� 雺挫殨瓿� 旒�鞚措Ж 鞝滊弰搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞏戩浮 氇憪 雼弲 霕愲姅 瓿惦彊鞚� 鞚橁舶甓屄缝矘攵勱秾鞚� 鞐嗠嫟瓿� 氚濏瀳瓿� 鞛堨溂氅�, 頃措嫻 歃濌秾鞚� 氚滍枆須岇偓 歆�氚办棎 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑頃橃 鞎婌晿鞚岇潉 歃濍獏頃╇媹雼�. 鞝滌稖靹滊姅 霊� 氩曥澑鞚� 鞙勴暣 Michael Kramarz臧� 靹滊獏頄堨溂氅� 瓿惦彊 鞝滌稖 瓿勳暯靹滊ゼ 觳秬鞛愲搿� 鞏戈笁頃╇媹雼�.
D茅p么t Schedule 13G/A de Solid Biosciences Inc. par des entit茅s Commodore Capital
Commodore Capital LP et Commodore Capital Master LP ont d茅pos茅 un amendement au Schedule 13G d茅clarant d茅tenir z茅ro action de Solid Biosciences Inc. (CUSIP 83422E204), soit 0,0 % de la cat茅gorie. Le dossier indique le si猫ge principal de l'茅metteur au 500 Rutherford Avenue, Charlestown, Massachusetts, et fournit les adresses de d茅p么t des deux d茅clarants 脿 New York et aux 卯les Ca茂mans. Les deux d茅clarants pr茅cisent ne d茅tenir ni pouvoir de vote ni pouvoir de disposition, ni exclusif ni partag茅, sur aucune action et certifient que ces titres n'ont pas 茅t茅 acquis dans le but d'influencer le contr么le de l'茅metteur. Le d茅p么t est sign茅 par Michael Kramarz pour les deux entit茅s et renvoie 脿 un accord de d茅p么t conjoint en annexe.
Schedule 13G/A von Solid Biosciences Inc. eingereicht durch Commodore Capital-Einheiten
Commodore Capital LP und Commodore Capital Master LP haben eine 脛nderung zum Schedule 13G eingereicht und melden dabei null Aktien von Solid Biosciences Inc. (CUSIP 83422E204) 鈥� entsprechend 0,0% der Klasse. Die Einreichung nennt den Hauptsitz des Emittenten in 500 Rutherford Avenue, Charlestown, Massachusetts, und gibt die Einreichungsadressen der beiden Melder in New York und auf den Cayman Islands an. Beide geben an, weder alleinige noch gemeinsame Stimmberechtigung oder Verf眉gungsgewalt 眉ber irgendwelche Aktien zu besitzen, und best盲tigen, dass die Wertpapiere nicht zum Zwecke der Einflussnahme auf die Kontrolle des Emittenten erworben wurden. Das Dokument ist f眉r beide Einheiten von Michael Kramarz unterzeichnet und verweist auf eine gemeinsame Einreichungsvereinbarung als Anhang.
FAQ
What did Commodore Capital report on the Schedule 13G/A for SLDB?
Who signed the Schedule 13G/A amendment for Solid Biosciences (SLDB)?
Does the filing indicate the filers have voting or dispositive power over SLDB shares?
What addresses are listed for the issuer and filers in the Schedule 13G/A?
Does the filing state the filers intend to influence control of Solid Biosciences?
